Ratings NEXTIN, Inc.

Equities

A348210

KR7348210006

End-of-day quote Korea S.E. 06:00:00 2024-04-24 pm EDT 5-day change 1st Jan Change
61,400 KRW +2.33% Intraday chart for NEXTIN, Inc. -2.23% -11.53%

Summary

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
  • From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Strengths

  • According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
  • The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
  • The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
  • Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.

Weaknesses

  • With an enterprise value anticipated at 4574.16 times the sales for the current fiscal year, the company turns out to be overvalued.
  • The company appears highly valued given the size of its balance sheet.
  • The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
  • For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
  • The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
  • For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
  • For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
  • Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

Ratings chart - Surperformance

Sector: Semiconductor Equipment & Testing

1st Jan change Capi. Investor Rating ESG Refinitiv
-11.53% 444M -
+22.30% 351B
B
+15.09% 116B
B
+33.04% 104B
B+
+7.41% 19.54B
B+
+7.28% 19.27B
C+
+36.04% 10.33B
B+
+19.25% 8.7B
B
-9.56% 7.35B
C+
+28.12% 5.41B
B+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality